NeuroBo Pharmaceuticals, Inc. (NASDAQ:NRBO – Get Free Report)’s stock price dropped 3.6% on Monday . The stock traded as low as $2.92 and last traded at $2.92. Approximately 15,669 shares traded hands during mid-day trading, a decline of 96% from the average daily volume of 446,519 shares. The stock had previously closed at $3.03.
NeuroBo Pharmaceuticals Trading Down 1.7 %
The business’s 50 day moving average price is $3.26 and its 200-day moving average price is $3.76.
NeuroBo Pharmaceuticals (NASDAQ:NRBO – Get Free Report) last released its earnings results on Wednesday, August 14th. The company reported ($1.85) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.38) by ($0.47). Research analysts predict that NeuroBo Pharmaceuticals, Inc. will post -4.39 EPS for the current year.
Institutional Investors Weigh In On NeuroBo Pharmaceuticals
About NeuroBo Pharmaceuticals
NeuroBo Pharmaceuticals, Inc, a clinical-stage biotechnology company focuses on developing and commercializing novel pharmaceuticals to treat cardiometabolic diseases. It develops DA-1241, a novel G-Protein-Coupled Receptor 119 agonist with development optionality as a standalone and/or combination therapy that is in Phase 2a clinical trial for metabolic dysfunction-associated steatohepatitis (MASH), and has completed Phase 1 clinical trial for the treatment of type 2 diabetes mellitus (T2DM); and DA-1726, a novel oxyntomodulin analogue functioning as a GLP-1 receptor and glucagon receptor dual agonist, which is in preclinical development for the treatment of obesity.
See Also
- Five stocks we like better than NeuroBo Pharmaceuticals
- Unveiling The Power Of VWAP: A Key Indicator For Traders
- Chinese Stocks Cool Off: Time to Buy the Dip in These 2 Stocks?
- 5 discounted opportunities for dividend growth investors
- Goldman Sachs Highlights 3 Top Short Squeeze Stocks to Watch
- The 3 Best Blue-Chip Stocks to Buy Now
- Walmart is Up 56% YTD, Is it Still a Top Consumer Staples Stock?
Receive News & Ratings for NeuroBo Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NeuroBo Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.